Ahead of its IPO, Suraksha Diagnostic Limited, situated in Kolkata, has raised Rs. 253 crores from 16 anchor investors. Leading names such as Carnelian Bharat Amritkaal Fund, Societe Generale, Integrated Core Strategies (Asia), Troo Capital, and Tusk Investments were allotted shares in the anchor book, along with mutual funds like Aditya Birla Sunlife MF, Bandhan MF, JM Financial, Kotak MF, Mirae Asset MF, Nippon MF, and Quant MF.

Dr. Somnath Chatterjee, Chairman & Joint MD, of Suraksha Diagnostic, and Ms. Ritu Mittal, Joint MD, and CEO, of Suraksha Diagnostic shed light on the IPO offerings of Suraksha.

The price range for Suraksha Diagnostic’s initial public offering (IPO) is Rs 420 per equity share to Rs 441 per equity share, and it opens on Friday, November 29, 2024, and ends on Tuesday, December 3, 2024.

A one-stop shop for integrated diagnostics, Suraksha Diagnostics provides radiology and pathology testing as well as medical consultation services.

More than 2,300 examinations covering a variety of specialties and subjects are available from Suraksha. 788 routine pathology tests, 664 specialized pathology tests, and 766 radiology tests are available on its diagnostic test menu. These range from simple X-rays, ultrasounds, and computerized tomography (CT) scans to 119 advanced radiology tests, including magnetic resonance imaging (MRI) and specialized CT scans. It served over 1.14 million patients and performed about 5.98 million tests in Fiscal 2024.

The diagnostics services market in India is expected to reach roughly Rs 127,500 crores by Fiscal 2028, having grown from an estimated Rs 86,000 crores in Fiscal 2024, according to the CRISIL Report.

Furthermore, the eastern and northeastern regions of India were valued at around Rs 17,000 crores in Fiscal 2024 and are expected to increase at a compound annual growth rate (CAGR) of roughly 10.5% to 12.5% to reach about Rs 26,000 crores by Fiscal 2028.

Priyanka Dutta